Venbio Global Strategic Fund, L.p. - Net Worth and Insider Trading

Venbio Global Strategic Fund, L.p. Net Worth

The estimated net worth of Venbio Global Strategic Fund, L.p. is at least $14 Million dollars as of 2024-11-13. Venbio Global Strategic Fund, L.p. is the of ALX Oncology Holdings Inc and owns about 9,799,331 shares of ALX Oncology Holdings Inc (ALXO) stock worth over $13 Million. Venbio Global Strategic Fund, L.p. is the Director, 10% Owner of Precision BioSciences Inc and owns about 142,171 shares of Precision BioSciences Inc (DTIL) stock worth over $1 Million. Venbio Global Strategic Fund, L.p. is also the 10% Owner of Metacrine Inc and owns about 2,443,421 shares of Metacrine Inc (MTCR) stock worth over $3,421. Details can be seen in Venbio Global Strategic Fund, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Venbio Global Strategic Fund, L.p. has not made any transactions after 2021-10-25 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Venbio Global Strategic Fund, L.p.

To

Venbio Global Strategic Fund, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Venbio Global Strategic Fund, L.p. owns 3 companies in total, including Metacrine Inc (MTCR) , ALX Oncology Holdings Inc (ALXO) , and Precision BioSciences Inc (DTIL) .

Click here to see the complete history of Venbio Global Strategic Fund, L.p.’s form 4 insider trades.

Insider Ownership Summary of Venbio Global Strategic Fund, L.p.

Ticker Comapny Transaction Date Type of Owner
MTCR Metacrine Inc 2021-10-25 10 percent owner & other: See Remarks
ALXO ALX Oncology Holdings Inc 2020-07-21 10 percent owner & other: See Remarks
DTIL Precision BioSciences Inc 2019-04-01 director & 10 percent owner

Venbio Global Strategic Fund, L.p. Latest Holdings Summary

Venbio Global Strategic Fund, L.p. currently owns a total of 3 stocks. Among these stocks, Venbio Global Strategic Fund, L.p. owns 9,799,331 shares of ALX Oncology Holdings Inc (ALXO) as of July 21, 2020, with a value of $13 Million and a weighting of 91.7%. Venbio Global Strategic Fund, L.p. owns 142,171 shares of Precision BioSciences Inc (DTIL) as of April 1, 2019, with a value of $1 Million and a weighting of 8.28%. Venbio Global Strategic Fund, L.p. also owns 2,443,421 shares of Metacrine Inc (MTCR) as of October 25, 2021, with a value of $3,421 and a weighting of 0.02%.

Latest Holdings of Venbio Global Strategic Fund, L.p.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ALXO ALX Oncology Holdings Inc 2020-07-21 9,799,331 1.35 13,229,097
DTIL Precision BioSciences Inc 2019-04-01 142,171 8.40 1,194,236
MTCR Metacrine Inc 2021-10-25 2,443,421 0.00 3,421

Holding Weightings of Venbio Global Strategic Fund, L.p.


Venbio Global Strategic Fund, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Venbio Global Strategic Fund, L.p. has made a total of 1 transactions in ALX Oncology Holdings Inc (ALXO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in ALX Oncology Holdings Inc is the acquisition of 853,000 shares on July 21, 2020, which cost Venbio Global Strategic Fund, L.p. around $16 Million.

According to the SEC Form 4 filings, Venbio Global Strategic Fund, L.p. has made a total of 0 transactions in Precision BioSciences Inc (DTIL) over the past 5 years. The most-recent trade in Precision BioSciences Inc is the acquisition of 1,667 shares on April 1, 2019, which cost Venbio Global Strategic Fund, L.p. around $800,000.

According to the SEC Form 4 filings, Venbio Global Strategic Fund, L.p. has made a total of 2 transactions in Metacrine Inc (MTCR) over the past 5 years, including 1 buys and 1 sells. The most-recent trade in Metacrine Inc is the sale of 615,702 shares on October 25, 2021, which brought Venbio Global Strategic Fund, L.p. around $929,710.

Insider Trading History of Venbio Global Strategic Fund, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Venbio Global Strategic Fund, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Venbio Global Strategic Fund, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Venbio Global Strategic Fund, L.p. is 0.83%. GuruFocus also compares Venbio Global Strategic Fund, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Venbio Global Strategic Fund, L.p. within 3 months outperforms 1 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Venbio Global Strategic Fund, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Venbio Global Strategic Fund, L.p.

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 3 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 9.9 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 6.16 LIMIT LIMIT LIMIT LIMIT LIMIT

Venbio Global Strategic Fund, L.p. Ownership Network

Ownership Network List of Venbio Global Strategic Fund, L.p.

No Data

Ownership Network Relation of Venbio Global Strategic Fund, L.p.

Insider Network Chart

Venbio Global Strategic Fund, L.p. Owned Company Details

What does Metacrine Inc do?

Who are the key executives at Metacrine Inc?

Venbio Global Strategic Fund, L.p. is the 10 percent owner & other: See Remarks of Metacrine Inc. Other key executives at Metacrine Inc include Chief Business Officer Michael York , director & President & CEO Preston Klassen , and 10 percent owner Braden Michael Leonard .

Metacrine Inc (MTCR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Metacrine Inc (MTCR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Metacrine Inc (MTCR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Metacrine Inc (MTCR)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Metacrine Inc Insider Transactions

No Available Data

Venbio Global Strategic Fund, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Venbio Global Strategic Fund, L.p.. You might contact Venbio Global Strategic Fund, L.p. via mailing address: 1700 Owens Street, Suite 595, San Francisco Ca 94158.